SDSC
(Carcinome sino-nasal SMARCB1-déficient)

Skip to content

An Underrecognized SMARCB1 Entity

We are particularly focused on raising awareness of SMARCB1-deficient sinonasal carcinoma (SDSC) among pathologists, medical teams, sinonasal cancer patients, and the general public. We provide support to SDSC patients and strive to connect them with specialized multidisciplinary teams and SMARCB1 research scientists for guidance and optimal treatment.

SDSC is one of the lesser-known members of the SMARCB1 cancer family, yet it touches a broader age group (from adolescence to old age) than most of the others. First described in 2014, and with fewer than 200 cases reported worldwide, SDSC remains an underrecognized distinct sinonasal tumor entity. Many pathologists and oncology teams, including those with experience in head and neck pathology, have little or no experience with it.

Often confused with other sinonasal tumors, SDSC is challenging to diagnose on morphology alone, and several extra biopsy genetic tests than would ordinarily be done are required. SDSC is often misdiagnosed, yet getting a correct diagnosis early on is very important to establish the best treatment plan possible. SMARCA4-deficient sinonasal carcinoma, a very similar tumor entity of the same family, is even less known than SDSC. 
Differential diagnoses for SDSC include: sinonasal undifferentiated carcinoma (SNUC), poorly differentiated sinonasal carcinoma, NUT midline carcinoma, myoepithelial carcinoma, high grade neuroendocrine carcinoma, HPV-related multiphenotypic sinonasal carcinoma, adamantinoma-like Ewing sarcoma, and others.

We want to hear from you. Please contact us and we will get back to you quickly.

Medical & Research Centers for SDSC

If you or a loved one has received an SDSC diagnosis or would like a second reading of your sinonasal tumor biopsy, below is an initial list of contacts at hospitals and research centers with SMARCB1 and SDSC knowledge and experience. Because SMARCB1-deficient cancers have historically been more studied in the pediatric population, specialized pediatric oncologists are often well placed to put young adult and older patients in touch with the right specialists. Do not hesitate to reach out to them for help and guidance, regardless of your age and where you live.

This is a growing list. Please get back to us with other contacts and centers, so we can help patients the world over get the best care possible!

ÉTATS-UNIS

National Cancer Institute at the NIH Nyall London Johns Hopkins Medicine Shirley Su MD Anderson Mrinal Gounder Memorial Sloane Kettering Cancer Center Garret Choby University of Pittsburg Cancer Center

ROYAUME-UNI

Matt Lechner UCL Cancer Institute Kevin Harrington

DANEMARK

Karsten Nysom Copenhagen University Hospitals

France

Benjamin Verillaud APHP Sophie Postel-Vinay Gustave Roussy Christophe Le Tourneau Gustave Roussy Franck Bourdeaut Institut Curie

ALLEMAGNE

Michael Frühwald Augsburg University Hospital Philippe Jurmeister Ludwig-Maximilians Universität München Felix Sahm

Hong Kong

Victor Ho-Fun Lee Gleneagles

ITALIE

Paolo Bossi Humanitas Research Hospital Andrea Ferrari Istituto Nazionale dei Tumori di Milano Lisa Licitra Istituto Nazionale dei Tumori di Milano

ESPAGNE

Mario Hermsen ISPA Instituto Universitario Oviedo José Luis Llorente

Groupes de soutien
pour les cancers sino-nasaux

Please note that awareness and understanding of SDSC is limited or inexistant, even in some of these groups. Help spread the word!

SMARCB1 Hope SMARCB1 Ini1-deficient sinonasal carcinoma SNUC Family Sinus Cancer Support Sinus and Nasal Cancer Support & Awareness CORSICA REFCOR Corasso Corasso Echangeons Head and Neck Cancer Alliance Head and Neck Cancer Research Trust The Swallows Head & Neck Cancer Support Group Ashley’s Purple Star Foundation Dedicated to Finding a Cure for SNUC

Publications scientifiques

SMARCB1-deficient Sinonasal Carcinoma Impact of Clinical Factors and Treatments on SMARCB1 (INI-1)-Deficient Sinonasal Carcinoma SMARCB1 (INI-1)-Deficient Sinonasal Carcinoma: A Systematic Review and Pooled Analysis of Treatment Outcomes Outcomes of SMARCB1-deficient sinonasal carcinoma: Largest single-center cross-sectional study SMARCB1/INI-1-Deficient sinonasal carcinoma demonstrates a poor prognosis but favorable clinical outcomes after PD-1/PD-L1 inhibitor therapy: A case series (INI-1)-deficient Sinonasal Carcinoma: A Series of 39 Cases Expanding the Morphological and Clinicopathological Spectrum of a Recently Described Entity SMARCB1-deficient Sinonasal Carcinoma: Expanding the Pathologic Spectrum With a Series of 32 Cases INI‐1 (SMARCB1)–Deficient Undifferentiated Sinonasal Carcinoma: Novel Paradigm of Molecular Testing in the Diagnosis and Management of Sinonasal Malignancies Assessment of targeted therapy opportunities in sinonasal cancers using patient-derived functional tumor models A Case of SMARCB1-Deficient Sinonasal Carcinoma With Clear Cell Morphology DNA methylation-based classification of sinonasal tumors SMARCB1/INI1 Deficient Sino-Nasal Carcinoma: Extending the Histomorphological Features Biomarkers for Immunotherapy in Poorly Differentiated Sinonasal Tumors Immunotherapy in SMARCB1 (INI-1)-deficient sinonasal carcinoma: Two case reports SMARCB1-deficient sinonasal adenocarcinoma: a rare variant of SWI/SNF-deficient malignancy often misclassified as high-grade non-intestinal-type sinonasal adenocarcinoma or myoepithelial carcinoma Sinonasal Cancer: Improving Classification, Stratification and Therapeutic Options Proceedings of the North American Society of Head and Neck Pathology, Los Angeles, CA, March 20, 2022: SWI/SNF-deficient Sinonasal Neoplasms: An Overview SMARCB1(INI1)-deficient Sinonasal Basaloid Carcinoma
A Novel Member of the Expanding Family of SMARCB1-deficient Neoplasms